Targeting IFN-γ to the tumor microenvironment via EDA or EDB resulted in enhanced tumor and liver metastasis control when compared to a non-specific IFN-γ immunocytokine in teratocarcinoma models, sarcoma, and Lewis lung carcinoma (LLC) models. Here, IFNG is linked to neoplasm.